Intervention

Epirubicin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 125 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials125

Recruiting18

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · 2026-03-06

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCNCT07016399 · 2025-09-09

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerNCT06860529 · 2025-04-15

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerNCT06291064 · 2025-03-18

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerNCT06389006 · 2024-04-29

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT06121570 · 2023-11-01

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerNCT05900206 · 2023-10-26

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyNCT05978648 · 2023-09-20

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT05981014 · 2023-08-01

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerNCT05883852 · 2023-06-07

TCb vs EC-T in High Risk ER+/HER2- Breast CancerNCT05901428 · 2023-06-01

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)NCT05447702 · 2022-11-01

A Study for the Adjuvant Treatment of Breast CancerNCT05420467 · 2022-07-10

A Study for the Neoadjuvant Treatment of Breast CancerNCT05420454 · 2022-07-10

MicroRNA Profiles in Triple Negative Breast CancerNCT04771871 · 2021-11-29

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast CancerNCT04576143 · 2020-09-20

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNCT06470633 · 2024-08-01

NOT_YET_RECRUITING

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNCT06404463 · 2024-05-06

NOT_YET_RECRUITING

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14

ACTIVE_NOT_RECRUITING

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNCT05983094 · 2023-09-01

NOT_YET_RECRUITING

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerNCT05491694 · 2022-09-01

Neoadjuvant Treatment of Breast CancerNCT05131893 · 2022-03-01

NOT_YET_RECRUITING

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast CancerNCT05681728 · 2022-02-01

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCNCT04877821 · 2021-09-15

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyNCT05656079 · 2021-07-01

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerNCT04717531 · 2021-06-03

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerNCT04872985 · 2021-04-20

ACTIVE_NOT_RECRUITING

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyNCT04770272 · 2021-03-01

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast CancerNCT04498793 · 2020-09-01

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)NCT04676997 · 2020-05-20

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)NCT04296175 · 2020-03-05

ACTIVE_NOT_RECRUITING

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerNCT04290793 · 2020-03-01

ACTIVE_NOT_RECRUITING

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerNCT04193059 · 2019-12-20

ACTIVE_NOT_RECRUITING

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerNCT03894007 · 2019-05-23

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyNCT03876886 · 2019-02-22

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCNCT04172259 · 2019-01-10

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerNCT03756090 · 2018-12-01

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerNCT03647280 · 2018-12-01

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast CancerNCT03556358 · 2018-06-28

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCNCT03289819 · 2018-03-23

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer PatientsNCT03013504 · 2018-02-19

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast CancerNCT03373708 · 2017-12-20

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant ChemotherapyNCT03349177 · 2017-11-27

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsNCT03272477 · 2017-10-05

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsNCT04659551 · 2017-10-05

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.NCT03356860 · 2017-04-13

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · 2017-03-07

Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · 2017-02-13

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer PatientsNCT03123770 · 2016-12-01

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerNCT02897050 · 2016-09-01

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast CancerNCT03273595 · 2016-07-01

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerNCT02685059 · 2016-06-01

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerNCT02742051 · 2016-06-01

Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer PatientsNCT02694224 · 2016-04-01

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast CancerNCT02549677 · 2015-10-01

Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By SurgeryNCT02627248 · 2015-10-01

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast CancerNCT04224922 · 2015-05-01

A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCsNCT02510781 · 2015-01-01

Common conditions

Leading sponsors

Fudan University9 Hellenic Oncology Research Group8 M.D. Anderson Cancer Center7 GBG Forschungs GmbH5 Hoffmann-La Roche5 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University5 Spanish Breast Cancer Research Group4 Women's Cancer Study Group GmbH4 Cancer Institute and Hospital, Chinese Academy of Medical Sciences3 GlaxoSmithKline3 SCRI Development Innovations, LLC3 Second Affiliated Hospital, Zhejiang University, School of Medicine3 The First Affiliated Hospital with Nanjing Medical University3 UNICANCER3 Austrian Breast & Colorectal Cancer Study Group2

Trial status mix

COMPLETED59

UNKNOWN24

RECRUITING18

TERMINATED12

ACTIVE_NOT_RECRUITING5

NOT_YET_RECRUITING4

WITHDRAWN2

SUSPENDED1

Phase mix

PHASE274

PHASE342

PHASE16

NA5

PHASE45

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.